These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7701559)

  • 21. In vitro structure-function analysis of the beta-strand 326-333 of human p53.
    Chène P; Mittl P; Grütter M
    J Mol Biol; 1997 Nov; 273(4):873-81. PubMed ID: 9367778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fragmenting the S100B-p53 interaction: combined virtual/biophysical screening approaches to identify ligands.
    Agamennone M; Cesari L; Lalli D; Turlizzi E; Del Conte R; Turano P; Mangani S; Padova A
    ChemMedChem; 2010 Mar; 5(3):428-35. PubMed ID: 20077460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 Proteoforms and Intrinsic Disorder: An Illustration of the Protein Structure-Function Continuum Concept.
    Uversky VN
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
    Hainaut P; Milner J
    Cancer Res; 1993 Oct; 53(19):4469-73. PubMed ID: 8402615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for allosteric effects on p53 oligomerization induced by phosphorylation.
    Muller P; Chan JM; Simoncik O; Fojta M; Lane DP; Hupp T; Vojtesek B
    Protein Sci; 2018 Feb; 27(2):523-530. PubMed ID: 29124793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53: a glimpse at the puppet behind the shadow play.
    Friend S
    Science; 1994 Jul; 265(5170):334-5. PubMed ID: 8023155
    [No Abstract]   [Full Text] [Related]  

  • 29. Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis.
    Méplan C; Verhaegh G; Richard MJ; Hainaut P
    Proc Nutr Soc; 1999 Aug; 58(3):565-71. PubMed ID: 10604188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.
    Clore GM; Omichinski JG; Sakaguchi K; Zambrano N; Sakamoto H; Appella E; Gronenborn AM
    Science; 1994 Jul; 265(5170):386-91. PubMed ID: 8023159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The tetramer of p53 in the absence of DNA forms a relaxed quaternary state.
    Pham N; Lucumi A; Cheung N; Viadiu H
    Biochemistry; 2012 Oct; 51(41):8053-5. PubMed ID: 23025236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new era of studying p53-mediated transcription activation.
    Liu WL; Coleman RA; Singh SK
    Transcription; 2018; 9(2):102-107. PubMed ID: 28795863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformational effects of environmentally induced, cancer-related mutations in the p53 protein.
    Brandt-Rauf PW; Monaco R; Pincus MR
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9262-6. PubMed ID: 7937752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of the interaction between the p53 binding domain and the p21/CiP1 DNA response element: a novel architectural organization.
    Appella E; Nagaich AK; Zhurkin VB; Harrington RE
    J Protein Chem; 1998 Aug; 17(6):527-8. PubMed ID: 9723733
    [No Abstract]   [Full Text] [Related]  

  • 35. Structure of full-length p53 tumor suppressor probed by chemical cross-linking and mass spectrometry.
    Arlt C; Ihling CH; Sinz A
    Proteomics; 2015 Aug; 15(16):2746-55. PubMed ID: 25728495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.
    Gorina S; Pavletich NP
    Science; 1996 Nov; 274(5289):1001-5. PubMed ID: 8875926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solution conformation of an essential region of the p53 transactivation domain.
    Botuyan MV; Momand J; Chen Y
    Fold Des; 1997; 2(6):331-42. PubMed ID: 9427007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zinc binding and redox control of p53 structure and function.
    Hainaut P; Mann K
    Antioxid Redox Signal; 2001 Aug; 3(4):611-23. PubMed ID: 11554448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of two serine residues important for p53 DNA binding and protein stability.
    Wei G; Liu G; Liu X
    FEBS Lett; 2003 May; 543(1-3):16-20. PubMed ID: 12753897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Cho Y; Gorina S; Jeffrey PD; Pavletich NP
    Science; 1994 Jul; 265(5170):346-55. PubMed ID: 8023157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.